Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Nesfatin-1 Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Nucleobindin-2, DNA-binding protein NEFA, Gastric cancer antigen Zg4, NUCB2, NEFA
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


Availability on Request RD191227200R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate

Sample Requirements

20 µl/well

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.125–4 ng/ml

Limit of Detection

0.021 ng/ml

Intra-assay (Within-Run)

n = 8; CV = 4.3%

Inter-assay (Run-to-Run)

n = 6; CV = 5.9%

Spiking Recovery

99,90%

Dilution Linearity

107,90%

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 4 hours
  • The kit measures human nesfatin-1 in serum, plasma (EDTA, citrate, heparin)
  • Assay format is 96 wells
  • Standard is recombinant (E.coli) protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Energy metabolism and body weight regulation, Neural tissue markers

Summary

Nesfatin-1 was first described in 2006 as a neurohormone derived from the protein NEFA/nucleobindin2 (NUCB2). It is a polypeptide consisting of 82 amino acids, with high level of homology in human, mouse and rat. Nesfatin-1 has been localized in the brain, particulary in the nuclei of the hypothalamus, in the adipose tissue and the gastrointestinal tract, but also in serum and cerebrospinal fluid. Nesfatin-1 was identified as a satiety molecule affecting fat metabolism. Intracerebroven­tricular administration of nesfatin-1 induces decreases in food intake and body weight and increases in sympathetic nerve activity and mean arterial pressure. Effect of Nesfatin-1 is leptin – independent, it is probably mediated by melanocortin system. Several studies are currently focused on the possibility of using Nesfatin-1 in the treatment of obesity, even in individuals with leptin resistence. Due to the presence in serum Nesfatin-1 could also serve as a clinical marker in the diagnosis of many diseases. The important role of nesfatin-1 in metabolism of glucose and insulin has been reported in several studies. Different concentrations were observed in patients with diabetes mellitus type I. and II. In individuals with DM type II. postprandial concentration of nesfatin-1 was significantly lower than that of DM type I. and healthy subjects. Different levels of Nesfatin-1 was measured in patients with anorexia nervosa and panic disorders in comparison with a control healthy group. Data obtained in experiments with rat models indicate that nesfatin-1 acts as a peripheral modulator of the cardiac function. Much higher levels of serum Nesfatin-1 (up to 160×) were detected in patients with primarily diagnosed epilepsy. During the treatment with anti-epileptics concentration of Nesfatin-1 decreased, but it was still about 10 times higher that the level of the hormone in healthy individuals. It offers the idea that it would be possible to use the Nesfatin-1 as a marker for diagnosis and monitoring of epilepsy.

Product References (4)

References

  • Boutsikou T, Briana DD, Boutsikou M, Kafalidis G, Piatopoulou D, Baka S,Hassiakos D, Gourgiotis D, Malamitsi-Puchner A. Cord blood nesfatin-1 in largefor gestational age pregnancies. Cytokine. 2013 Feb;61(2):591-4. doi:10.1016/j.cyto.2012.10.029. Epub 2012 Nov 22. PubMed PMID: 23178145. See more on PubMed
  • Erek Toprak A, Ozlu E, Uzuncakmak TK, Yalcınkaya E, Sogut S, Karadag AS.Neutrophil/Lymphocyte Ratio, Serum Endocan, and Nesfatin-1 Levels in Patientswith Psoriasis Vulgaris Undergoing Phototherapy Treatment. Med Sci Monit. 2016Apr 12;22:1232-7. PubMed PMID: 27070789; PubMed Central PMCID: PMC4831300. See more on PubMed
  • Kim SH, Ahn MB, Cho WK, Cho KS, Jung MH, Suh BK. The relation of serumnesfatin-1 level with anthropometric and metabolic parameters in children andadolescents: A prospective observational study. Medicine (Baltimore). 2019May;98(19):e15460. doi: 10.1097/MD.0000000000015460. PubMed PMID: 31083178;PubMed Central PMCID: PMC6531266. See more on PubMed
  • Mierzyński R, Poniedziałek-Czajkowska E, Dłuski D, Patro-Małysza J,Kimber-Trojnar Ż, Majsterek M, Leszczyńska-Gorzelak B. Nesfatin-1 and Vaspin asPotential Novel Biomarkers for the Prediction and Early Diagnosis of Gestational Diabetes Mellitus. Int J Mol Sci. 2019 Jan 4;20(1). pii: E159. doi:10.3390/ijms20010159. PubMed PMID: 30621139; PubMed Central PMCID: PMC6337752. See more on PubMed
Summary References (17)

References to Nesfatin-1

  • Angelone T, Filice E, Pasqua T, Amodio N, Galluccio M, Montesanti G, Quintieri AM, Cerra MC. Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury. Cell Mol Life Sci. 2012 Sep 7;
  • Aydin S, Dag E, Ozkan Y, Arslan O, Koc G, Bek S, Kirbas S, Kasikci T, Abasli D, Gokcil Z, Odabasi Z, Catak Z. Time-dependent changes in the serum levels of prolactin, nesfatin-1 and ghrelin as a marker of epileptic attacks young male patients. Peptides. 2011 Jun;32 (6):1276-80
  • Aydin S, Dag E, Ozkan Y, Erman F, Dagli AF, Kilic N, Sahin I, Karatas F, Yoldas T, Barim AO, Kendir Y. Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders. Mol Cell Biochem. 2009 Aug;328 (1-2):49-56
  • Bez Y, Ari M et al. Plasma nesfatin-1 level may be associated with disease severity in patiens with panic disorders. Bull Clin Psychpharm. 2010;20:288-292
  • Bonnet MS, Djelloul M, Tillement V, Tardivel C, Mounien L, Trouslard J, Troadec JD, Dallaporta M. Central NUCB2/Nesfatin-1-Expressing Neurones Belong to the Hypothalamic-Brainstem Circuitry Activated by Hypoglycaemia. J Neuroendocrinol. 2013 Jan;25 (1):1-13
  • Brailoiu GC, Dun SL, Brailoiu E, Inan S, Yang J, Chang JK, Dun NJ. Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology. 2007 Oct;148 (10):5088-94
  • Garcia-Galiano D, Navarro VM, Roa J, Ruiz-Pino F, Sanchez-Garrido MA, Pineda R, Castellano JM, Romero M, Aguilar E, Gaytan F, Dieguez C, Pinilla L, Tena-Sempere M. The anorexigenic neuropeptide, nesfatin-1, is indispensable for normal puberty onset in the female rat. J Neurosci. 2010 Jun 9;30 (23):7783-92
  • Gonzalez R, Reingold BK, Gao X, Gaidhu MP, Tsushima RG, Unniappan S. Nesfatin-1 exerts a direct, glucose-dependent insulinotropic action on mouse islet beta- and MIN6 cells. J Endocrinol. 2011 Mar;208 (3):R9-R16
  • Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept. 2010 Jan 8;159 (1-3):72-7
  • Nakata M, Manaka K, Yamamoto S, Mori M, Yada T. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca(2+) influx through L-type channels in mouse islet beta-cells. Endocr J. 2011;58 (4):305-13
  • Ogiso K, Asakawa A, Amitani H, Nakahara T, Ushikai M, Haruta I, Koyama K, Amitani M, Harada T, Yasuhara D, Inui A. Plasma nesfatin-1 concentrations in restricting-type anorexia nervosa. Peptides. 2011 Jan;32 (1):150-3
  • Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, Tsuchiya T, Monden T, Horiguchi K, Yamada M, Mori M. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006 Oct 12;443 (7112):709-12
  • Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, Kern W, Hillhouse EW, Lehnert H, Tan BK, Randeva HS. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology. 2010 Jul;151 (7):3169-80
  • Riva M, Nitert MD, Voss U, Sathanoori R, Lindqvist A, Ling C, Wierup N. Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects. Cell Tissue Res. 2011 Dec;346 (3):393-405
  • Shimizu H, Oh-I S, Hashimoto K, Nakata M, Yamamoto S, Yoshida N, Eguchi H, Kato I, Inoue K, Satoh T, Okada S, Yamada M, Yada T, Mori M. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology. 2009 Feb;150 (2):662-71
  • Shimizu H, Oh-I S, Okada S, Mori M. Nesfatin-1: an overview and future clinical application. Endocr J. 2009;56 (4):537-43
  • Stengel A, Goebel M, Yakubov I, Wang L, Witcher D, Coskun T, Tache Y, Sachs G, Lambrecht NW. Identification and characterization of nesf
Related Products Docs